JP6466833B2 - 抗炎症活性を有するペプチド、及びそれを含む組成物 - Google Patents

抗炎症活性を有するペプチド、及びそれを含む組成物 Download PDF

Info

Publication number
JP6466833B2
JP6466833B2 JP2015510686A JP2015510686A JP6466833B2 JP 6466833 B2 JP6466833 B2 JP 6466833B2 JP 2015510686 A JP2015510686 A JP 2015510686A JP 2015510686 A JP2015510686 A JP 2015510686A JP 6466833 B2 JP6466833 B2 JP 6466833B2
Authority
JP
Japan
Prior art keywords
seq
peptide
disease
sequence number
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015510686A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015523323A (ja
JP2015523323A5 (enExample
Inventor
サン チェ キム
サン チェ キム
キョン ヘ キム
キョン ヘ キム
キュ−ヨン リ
キュ−ヨン リ
ソン−ホ コ
ソン−ホ コ
ヒョン−ヘ パク
ヒョン−ヘ パク
ソン チン フ
ソン チン フ
ウ チン リ
ウ チン リ
ポム チュン キム
ポム チュン キム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2015523323A publication Critical patent/JP2015523323A/ja
Publication of JP2015523323A5 publication Critical patent/JP2015523323A5/ja
Priority to JP2018108788A priority Critical patent/JP6923485B2/ja
Application granted granted Critical
Publication of JP6466833B2 publication Critical patent/JP6466833B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/99—Miscellaneous (1.14.99)
    • C12Y114/99001—Prostaglandin-endoperoxide synthase (1.14.99.1), i.e. cyclooxygenase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Birds (AREA)
JP2015510686A 2012-05-11 2013-03-15 抗炎症活性を有するペプチド、及びそれを含む組成物 Active JP6466833B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018108788A JP6923485B2 (ja) 2012-05-11 2018-06-06 抗炎症活性を有するペプチド、及びそれを含む組成物

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
KR10-2012-0050533 2012-05-11
KR20120050529 2012-05-11
KR10-2012-0050529 2012-05-11
KR20120050533 2012-05-11
KR20120071989 2012-07-02
KR10-2012-0071989 2012-07-02
KR10-2012-0104144 2012-09-19
KR10-2012-0104207 2012-09-19
KR20120104207 2012-09-19
KR20120104144 2012-09-19
PCT/EP2013/055327 WO2013167298A1 (en) 2012-05-11 2013-03-15 Anti-inflammatory peptides and composition comprising the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018108788A Division JP6923485B2 (ja) 2012-05-11 2018-06-06 抗炎症活性を有するペプチド、及びそれを含む組成物

Publications (3)

Publication Number Publication Date
JP2015523323A JP2015523323A (ja) 2015-08-13
JP2015523323A5 JP2015523323A5 (enExample) 2016-05-12
JP6466833B2 true JP6466833B2 (ja) 2019-02-06

Family

ID=47882179

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2015510686A Active JP6466833B2 (ja) 2012-05-11 2013-03-15 抗炎症活性を有するペプチド、及びそれを含む組成物
JP2015510786A Active JP6294306B2 (ja) 2012-05-11 2013-05-07 抗炎症活性を有するペプチド、及びそれを含む組成物
JP2017174211A Active JP6546232B2 (ja) 2012-05-11 2017-09-11 抗炎症活性を有するペプチド、及びそれを含む組成物
JP2018108788A Active JP6923485B2 (ja) 2012-05-11 2018-06-06 抗炎症活性を有するペプチド、及びそれを含む組成物
JP2019114719A Active JP7007333B2 (ja) 2012-05-11 2019-06-20 抗炎症活性を有するペプチド、及びそれを含む組成物
JP2021165541A Active JP7449909B2 (ja) 2012-05-11 2021-10-07 抗炎症活性を有するペプチド、及びそれを含む組成物
JP2024032114A Active JP7757448B2 (ja) 2012-05-11 2024-03-04 抗炎症活性を有するペプチド、及びそれを含む組成物

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2015510786A Active JP6294306B2 (ja) 2012-05-11 2013-05-07 抗炎症活性を有するペプチド、及びそれを含む組成物
JP2017174211A Active JP6546232B2 (ja) 2012-05-11 2017-09-11 抗炎症活性を有するペプチド、及びそれを含む組成物
JP2018108788A Active JP6923485B2 (ja) 2012-05-11 2018-06-06 抗炎症活性を有するペプチド、及びそれを含む組成物
JP2019114719A Active JP7007333B2 (ja) 2012-05-11 2019-06-20 抗炎症活性を有するペプチド、及びそれを含む組成物
JP2021165541A Active JP7449909B2 (ja) 2012-05-11 2021-10-07 抗炎症活性を有するペプチド、及びそれを含む組成物
JP2024032114A Active JP7757448B2 (ja) 2012-05-11 2024-03-04 抗炎症活性を有するペプチド、及びそれを含む組成物

Country Status (8)

Country Link
US (12) US9527888B2 (enExample)
EP (2) EP2850097B1 (enExample)
JP (7) JP6466833B2 (enExample)
KR (5) KR20150014483A (enExample)
CN (7) CN115927242A (enExample)
ES (3) ES3046661T3 (enExample)
TW (8) TWI640320B (enExample)
WO (3) WO2013167298A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2875826B1 (en) * 2012-05-11 2017-08-23 KAEL-GemVax Co.,Ltd Composition for preventing or treating sepsis
KR20150014483A (ko) 2012-05-11 2015-02-06 주식회사 카엘젬백스 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
EP2873678B8 (en) 2012-07-11 2024-07-17 Gemvax & Kael Co., Ltd. Conjugate comprising a cell-penetrating peptide and compositions comprising same
US20150125438A1 (en) 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
TWI616530B (zh) * 2012-09-19 2018-03-01 傑姆維克斯＆凱爾有限公司 穿膜胜肽以及包含該胜肽之共軛物及組成物（一）
ES2802253T3 (es) 2012-09-19 2021-01-18 Gemvax & Kael Co Ltd Péptido de penetración celular, conjugado que comprende el mismo y composición que comprende el conjugado
ES2999332T3 (en) * 2012-09-19 2025-02-25 Gemvax & Kael Co Ltd Cell penetrating peptide, conjugate comprising the same, and composition comprising conjugate
US9631184B2 (en) 2012-09-19 2017-04-25 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
ES2716870T3 (es) 2013-04-19 2019-06-17 Gemvax & Kael Co Ltd Composición para el tratamiento y prevención de lesión isquémica
CN105535931A (zh) 2013-06-07 2016-05-04 凯尔杰姆维克斯有限公司 在癌症免疫疗法中有用的生物标记
ES2808076T3 (es) 2013-06-21 2021-02-25 Gemvax & Kael Co Ltd Regulador de la secreción hormonal, composición que lo contiene y procedimiento para controlar la secreción hormonal mediante su uso
BR112016008331B1 (pt) 2013-10-23 2023-01-31 Sang Jae Kim Composição para tratar e prevenir hiperplasia prostática benigna (bhp) e uso da dita composição para tratar e prevenir bhp
WO2015076621A1 (ko) * 2013-11-22 2015-05-28 주식회사 카엘젬백스 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
KR20240073156A (ko) * 2013-12-10 2024-05-24 주식회사 젬백스앤카엘 항산화 효과를 가지는 펩티드 및 이를 포함하는 조성물
US11058744B2 (en) 2013-12-17 2021-07-13 Gemvax & Kael Co., Ltd. Composition for treating prostate cancer
JP6420459B2 (ja) * 2014-04-11 2018-11-07 ジェムバックス アンド カエル カンパニー，リミティド 線維症抑制活性を有するペプチド及びこれを含む組成物
CN106659149B (zh) * 2014-04-30 2020-05-19 珍白斯凯尔有限公司 用于器官、组织或细胞移植的组合物、试剂盒和移植方法
WO2015170790A1 (ko) * 2014-05-09 2015-11-12 주식회사 카엘젬백스 허혈성 손상 치료 및 예방용 조성물
KR102232319B1 (ko) * 2014-05-09 2021-03-26 주식회사 젬백스앤카엘 텔로머라제 펩티드를 유효성분으로 포함하는 뇌혈관 질환 예방 또는 치료용 조성물
KR102413243B1 (ko) * 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
EP3263122B1 (en) 2015-02-27 2020-05-06 Gemvax & Kael Co., Ltd. Peptide for preventing hearing loss, and composition comprising same
KR101662438B1 (ko) 2015-04-07 2016-10-04 가톨릭대학교 산학협력단 X형 구조의 dna를 유효성분으로 포함하는 아토피 피부염 예방 또는 치료용 조성물
US10463709B2 (en) * 2015-04-27 2019-11-05 Mackay Memorial Hospital Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
ES2879641T3 (es) * 2015-05-26 2021-11-22 Gemvax & Kael Co Ltd Octapéptidos antiinflamatorias, antifibróticos y cicatrizantes de heridas y las composiciones que los contienen
WO2017003267A1 (ko) * 2015-07-02 2017-01-05 주식회사 젬백스앤카엘 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물
CN105061573B (zh) * 2015-07-20 2018-08-21 苏州大学 姚虻天然抗炎症多肽cecropin-TY1及其应用
EP3372613A4 (en) * 2015-11-03 2019-07-10 Gemvax & Kael Co., Ltd. PEPTIDE WITH NERVE DAMAGE PREVENTION AND REGENERATION EFFECT AND COMPOSITION THEREOF
WO2017116138A1 (ko) * 2015-12-28 2017-07-06 주식회사 젬백스앤카엘 멜라닌 억제 기능성 펩티드 및 이를 포함하는 조성물
JP6573293B2 (ja) * 2016-03-09 2019-09-11 カイン サイエンス シーオー., エルティーディー.KINE SCIENCES Co., Ltd. 炎症性疾患の予防または治療用ペプチド及びこの用途
KR101897122B1 (ko) * 2016-03-09 2018-09-10 주식회사 바이오펩 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도
US9943566B2 (en) 2016-03-16 2018-04-17 Geoffrey Brooks Consultants, Llc NF-κB inhibitor composition for skin health
US10898540B2 (en) 2016-04-07 2021-01-26 Gem Vax & KAEL Co., Ltd. Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same
KR101831888B1 (ko) * 2016-04-15 2018-04-16 (주)케어젠 항염증 활성을 갖는 펩타이드 및 이의 용도
WO2017183942A2 (ko) * 2016-04-21 2017-10-26 주식회사 젬백스앤카엘 콜라겐 생성 증가 효능을 가지는 펩티드 및 이를 포함하는 조성물
WO2018014936A1 (en) * 2016-07-18 2018-01-25 Nuritas Limited Topical compositions
KR102042600B1 (ko) * 2018-02-13 2019-11-08 전북대학교산학협력단 항산화 및 항염증 활성을 갖는 홍갯지렁이 유래 신규 펩타이드 및 이의 이용
EP3802562A4 (en) * 2018-05-28 2022-06-01 Jiangyin Usun Pharmaceutical Co., Ltd. New pharmaceutical use
CN112824428B (zh) * 2019-11-21 2022-08-16 上海医药工业研究院 一种治疗肺疾病的生物肽及其应用
KR102354916B1 (ko) * 2020-02-11 2022-01-26 주식회사 쓰리빅스 신규 펩타이드 3ps_i014 및 이의 용도
KR102266613B1 (ko) * 2020-09-21 2021-06-18 자안바이오 주식회사 항염증 활성을 갖는 신규한 펩티드 및 이의 용도
KR102302984B1 (ko) * 2021-06-16 2021-09-17 주식회사 쓰리빅스 염증성 피부 질환 예방 또는 치료용 약학조성물
WO2022270478A1 (ja) * 2021-06-21 2022-12-29 国立大学法人北海道大学 抗ウイルス剤
CN113461776B (zh) * 2021-07-08 2023-05-16 南京财经大学 一种具有预防及治疗肠炎功能的小肽及其应用
US11724077B2 (en) * 2021-07-28 2023-08-15 Subhash Dhawan Therapeutic swabs for treating upper respiratory infections
CN114349821B (zh) * 2021-12-08 2024-01-16 南方医科大学珠江医院 蛙皮抗氧化肽及其基因在制药和抗皱化妆品的应用
KR102856378B1 (ko) 2022-09-30 2025-09-08 주식회사 젬백스앤카엘 4r 타우병증의 치료 또는 예방용 펩티드
AU2024285799A1 (en) * 2023-06-08 2025-12-18 Gemvax & Kael Co., Ltd. Composition comprising gv1001 for preventing or treating periodontal diseases and disorders caused by periodontal diseases
KR20240179073A (ko) 2023-06-23 2024-12-31 주식회사 젬백스앤카엘 신규 펩티드 및 이의 용도
CN116693612B (zh) * 2023-06-28 2025-02-18 禾美生物科技(浙江)有限公司 一种环肽及其用途
KR102800994B1 (ko) 2023-11-06 2025-04-29 주식회사 엘지에너지솔루션 무음극 코팅층 및 이를 포함하는 전고체 전지
CN117986337B (zh) * 2024-02-02 2024-08-16 杭州御寿生物科技有限公司 一种提高免疫力的益生菌组合物以及在治疗疾病中的应用
CN119320425B (zh) * 2024-11-08 2025-08-05 深圳市第二人民医院(深圳市转化医学研究院) 多肽aamp及其在镇痛抗炎中的应用
CN119552212B (zh) * 2025-01-26 2025-04-25 杭州康源食品科技有限公司 一种具有降尿酸活性的三肽lfp及其应用

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR930001915B1 (ko) 1990-06-27 1993-03-20 포항종합제철 주식회사 저온 소결 압전요업재료 제조방법
HU207799B (en) 1991-07-24 1993-06-28 Beres Export Import Rt Process for producing pharmaceutical composition for influencing the reticuloendothelial system, for treating chronic pain symptomes of degenerative locomotor disorders or tumors, and for treating mucoviscidosis
JP2000515523A (ja) 1996-07-22 2000-11-21 ザ・ビクトリア・ユニバーシティ・オブ・マンチェスター 創傷および線維性障害の治療における性ステロイド機能モジュレーターの使用
FI990655A7 (fi) * 1996-10-01 1999-06-01 Geron Corp Ihmistelomeraasin katalyyttinen alayksikkö
US6610839B1 (en) * 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
US6475789B1 (en) * 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
ATE361099T1 (de) 1997-05-15 2007-05-15 Chugai Pharmaceutical Co Ltd Heilmittel für kachexie
AU748442B2 (en) 1997-07-01 2002-06-06 Cambia Vertebrate telomerase genes and proteins and uses thereof
US7030211B1 (en) * 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
US6378526B1 (en) 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
IL132406A0 (en) 1998-10-21 2001-03-19 Pfizer Prod Inc Treatment of bph with cgmp elevators
US6815426B2 (en) 2001-02-16 2004-11-09 E. I. Du Pont De Nemours And Company Angiogenesis-inhibitory tripeptides, compositions and their methods of use
JP4228700B2 (ja) 2001-04-10 2009-02-25 日本新薬株式会社 慢性関節リウマチの治療剤
CN100556450C (zh) 2001-05-16 2009-11-04 耶达研究发展有限公司 Il-18抑制剂在治疗或预防脓毒症中的应用
AU2002363231A1 (en) 2001-10-29 2003-05-12 Baylor College Of Medicine Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen
US7786084B2 (en) 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
CN100569796C (zh) * 2002-01-29 2009-12-16 Posco公司 免疫调节肽
JP4430403B2 (ja) 2002-04-10 2010-03-10 メルク セローノ ソシエテ アノニム 線維化疾患の治療および／または予防のためのオステオプロテゲリンの使用
KR20050020987A (ko) 2002-06-12 2005-03-04 바이오겐 아이덱 엠에이 인코포레이티드 아데노신 수용체 길항제를 사용하여 허혈 재관류 손상을치료하는 방법
WO2005000227A2 (en) 2003-06-06 2005-01-06 Intermune, Inc. Methods of treating tnf-mediated disorders
AU2004248998A1 (en) 2003-06-25 2004-12-29 Takeda Pharmaceutical Company Limited Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activity
KR20050040517A (ko) 2003-10-29 2005-05-03 주식회사 오리엔트 허혈성 질환에 대한 저항성을 나타내는 형질전환 생쥐
DK1530965T3 (da) 2003-11-11 2006-07-17 Mattern Udo Kontrolleret frigivelsesleveringssystem til nasal applikation
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
EP2374458A1 (en) 2005-03-21 2011-10-12 Vicus Therapeutics SPE 1, LLC Combination of an ACE inhibitor and an NSAID for use in ameliorating cachexia/SIRS
TW200803894A (en) 2005-11-25 2008-01-16 Univ Keio Prostate cancer therapeutic agents
EP1968643A2 (en) 2005-12-16 2008-09-17 Diatos Cell penetrating peptide conjugates for delivering of nucleic acids into a cell
EP1969141A4 (en) * 2005-12-23 2009-01-21 Sienna Cancer Diagnostics Ltd TEST FOR DETECTING TELOMERASE ACTIVITY
EP1991560B1 (en) 2006-02-20 2018-04-04 Ewha University-Industry Collaboration Foundation Peptide having cell membrane penetrating activity
EP2044108A4 (en) 2006-07-24 2010-06-30 Forhumantech Co Ltd PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND TREATMENT OF ISCHEMIC SUDIDS AND METHOD FOR THEIR ADMINISTRATION
JP5518488B2 (ja) 2007-01-29 2014-06-11 プロセル セラピューティックス インコーポレーティッド 巨大分子伝達ドメインならびにその同定方法および使用
CA2691980C (en) 2007-06-29 2022-05-10 Correlogic Systems, Inc. Predictive markers for ovarian cancer
US8933197B2 (en) 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
WO2009025871A1 (en) * 2007-08-23 2009-02-26 University Of Medicine And Dentistry Of Nj Telomerase reverse transcriptase variant
EP2212696B1 (en) 2007-10-25 2013-12-04 Genelux Corporation Systems and methods for viral therapy
GB2455539B (en) 2007-12-12 2012-01-18 Cambridge Entpr Ltd Anti-inflammatory compositions and combinations
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
JP5787752B2 (ja) * 2008-06-16 2015-09-30 メディオラヌム・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ 抗腫瘍免疫療法
US8252282B2 (en) 2008-06-19 2012-08-28 University Of Medicine & Dentistry Of New Jersey Nuclear telomerase reverse transcriptase variant
ES2334315B1 (es) 2008-07-29 2011-02-28 Universitat Pompeu Fabra Peptidos con capacidad de penetracion celular y sus usos.
CA2734487A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US20110183925A1 (en) 2008-09-22 2011-07-28 Nisshin Pharma Inc. Anti-inflammatory peptide
EP2337795A2 (en) 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
KR101169030B1 (ko) 2009-01-21 2012-07-26 애니젠 주식회사 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템
US8596445B2 (en) 2009-04-20 2013-12-03 Otis Elevator Company Balustrade and deck mounting assembly for a passenger conveyor
JP5826742B2 (ja) 2009-05-07 2015-12-02 ドンコック ファーマシューティカル カンパニー リミテッド 神経損傷及び神経疾患の予防または治療用薬学組成物
EP2251028A1 (en) 2009-05-12 2010-11-17 Biocompatibles Uk Ltd. Treatment of eye diseases using encapsulated cells encoding and secreting an anti-angiogenic factor and/or a neuroprotective factor
US7928067B2 (en) 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
CA2762551C (en) 2009-05-20 2016-11-22 Toray Industries, Inc. Cell-penetrating peptides
KR20110057049A (ko) 2009-11-23 2011-05-31 박의신 기능성 전립선염 치료제
KR20110062943A (ko) 2009-12-04 2011-06-10 주식회사종근당 퀴나졸린 유도체를 유효성분으로 하는 전립선 비대증 예방 또는 치료제
ES2664866T3 (es) 2010-01-11 2018-04-23 Curna, Inc. Tratamiento de enfermedades relacionadas con la globulina fijadora de hormonas sexuales (shbg) mediante inhibición del transcrito antisentido natural a shbg
EP3581649A1 (en) * 2010-02-16 2019-12-18 Ultimovacs ASA Polypeptides
FR2960542B1 (fr) 2010-05-27 2012-08-17 Esther Suzy Arlette Fellous Peptide en tant que medicament, en particulier pour le traitement du cancer
KR101263212B1 (ko) 2010-05-28 2013-05-10 성신여자대학교 산학협력단 신규한 세포막 투과성 펩타이드 및 그의 용도
WO2011150493A1 (en) 2010-05-30 2011-12-08 The Governing Council Of The University Of Toronto Mitochondrial penetrating peptides as carriers for antimicrobials
KR101388372B1 (ko) 2010-06-11 2014-04-23 한국화학연구원 청각보호 작용을 하는 신규 화합물
KR101348284B1 (ko) 2010-09-09 2014-01-03 주식회사 나이벡 인간 유래 세포 투과성 펩타이드와 생리활성 펩타이드 결합체 및 그 용도
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
KR20120121196A (ko) 2011-04-26 2012-11-05 주식회사 글루칸 관절염 치료제
KR101284772B1 (ko) 2011-05-24 2013-07-17 정종문 항염증, 진통효과를 가지는 기능성 식품 조성물
KR20120133661A (ko) 2011-05-31 2012-12-11 주식회사 바이오포트코리아 아스타잔틴을 포함하는 항염증제
KR101288053B1 (ko) 2011-07-04 2013-07-23 동국대학교 산학협력단 필발 추출물을 유효성분으로 포함하는 내이손상 예방 및 치료용 조성물
KR101361445B1 (ko) 2011-12-26 2014-02-12 성균관대학교산학협력단 펩타이드, 5-플루오로우라실, 및 성숙수지상세포를 포함하는 암 치료용 약학적 조성물
SG11201404570WA (en) 2012-02-10 2014-11-27 Hakushinkouseikai Foundation Proliferating agent for monocyte, culture medium for proliferating monocyte, method for producing monocyte, method for producing dendritic cell, and method for producing dendritic cell vaccine
KR102041381B1 (ko) 2012-03-12 2019-11-27 젬백스 에이에스 능동적인 면역치료법을 이용한 비-소세포성 폐암의 치료
EP2875826B1 (en) * 2012-05-11 2017-08-23 KAEL-GemVax Co.,Ltd Composition for preventing or treating sepsis
KR20150014483A (ko) 2012-05-11 2015-02-06 주식회사 카엘젬백스 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
EP2873678B8 (en) 2012-07-11 2024-07-17 Gemvax & Kael Co., Ltd. Conjugate comprising a cell-penetrating peptide and compositions comprising same
US20150125438A1 (en) 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
US9631184B2 (en) 2012-09-19 2017-04-25 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
ES2802253T3 (es) 2012-09-19 2021-01-18 Gemvax & Kael Co Ltd Péptido de penetración celular, conjugado que comprende el mismo y composición que comprende el conjugado
KR102038487B1 (ko) 2012-09-19 2019-10-30 주식회사 젬백스앤카엘 텔로머라제 펩티드를 포함하는 항균 또는 항진균용 조성물
ES2999332T3 (en) 2012-09-19 2025-02-25 Gemvax & Kael Co Ltd Cell penetrating peptide, conjugate comprising the same, and composition comprising conjugate
KR20140104288A (ko) 2013-02-20 2014-08-28 주식회사 카엘젬백스 Tnf-알파 저해제
ES3047667T3 (en) 2013-02-22 2025-12-04 Univ Leland Stanford Junior Methods relating to telomere extension
ES2716870T3 (es) 2013-04-19 2019-06-17 Gemvax & Kael Co Ltd Composición para el tratamiento y prevención de lesión isquémica
CN105535931A (zh) 2013-06-07 2016-05-04 凯尔杰姆维克斯有限公司 在癌症免疫疗法中有用的生物标记
ES2808076T3 (es) 2013-06-21 2021-02-25 Gemvax & Kael Co Ltd Regulador de la secreción hormonal, composición que lo contiene y procedimiento para controlar la secreción hormonal mediante su uso
KR102224965B1 (ko) 2013-07-12 2021-03-09 주식회사 젬백스앤카엘 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트
BR112016008331B1 (pt) 2013-10-23 2023-01-31 Sang Jae Kim Composição para tratar e prevenir hiperplasia prostática benigna (bhp) e uso da dita composição para tratar e prevenir bhp
WO2015076621A1 (ko) 2013-11-22 2015-05-28 주식회사 카엘젬백스 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
US11058744B2 (en) 2013-12-17 2021-07-13 Gemvax & Kael Co., Ltd. Composition for treating prostate cancer
JP6420459B2 (ja) 2014-04-11 2018-11-07 ジェムバックス アンド カエル カンパニー，リミティド 線維症抑制活性を有するペプチド及びこれを含む組成物
CN106659149B (zh) 2014-04-30 2020-05-19 珍白斯凯尔有限公司 用于器官、组织或细胞移植的组合物、试剂盒和移植方法
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
EP3263122B1 (en) 2015-02-27 2020-05-06 Gemvax & Kael Co., Ltd. Peptide for preventing hearing loss, and composition comprising same
ES2879641T3 (es) 2015-05-26 2021-11-22 Gemvax & Kael Co Ltd Octapéptidos antiinflamatorias, antifibróticos y cicatrizantes de heridas y las composiciones que los contienen
WO2017066349A1 (en) 2015-10-13 2017-04-20 Symic Ip, Llc Ve-cadherin binding bioconjugate
EP3372613A4 (en) 2015-11-03 2019-07-10 Gemvax & Kael Co., Ltd. PEPTIDE WITH NERVE DAMAGE PREVENTION AND REGENERATION EFFECT AND COMPOSITION THEREOF
KR20170054310A (ko) 2015-11-09 2017-05-17 주식회사 젬백스앤카엘 텔로머라제 유래 펩티드를 포함하는 수지상세포 치료제 및 면역 치료제, 및 이를 사용하는 치료방법

Also Published As

Publication number Publication date
TWI640320B (zh) 2018-11-11
EP3428181A3 (en) 2019-02-20
JP7449909B2 (ja) 2024-03-14
TWI784394B (zh) 2022-11-21
TWI640632B (zh) 2018-11-11
CN116694597A (zh) 2023-09-05
KR20220061282A (ko) 2022-05-12
TW202132324A (zh) 2021-09-01
JP2015523323A (ja) 2015-08-13
TW201800578A (zh) 2018-01-01
US12171812B2 (en) 2024-12-24
JP2019194216A (ja) 2019-11-07
US20210228690A1 (en) 2021-07-29
JP7007333B2 (ja) 2022-01-24
US20210085757A1 (en) 2021-03-25
JP6294306B2 (ja) 2018-03-14
JP2022001591A (ja) 2022-01-06
TW202417463A (zh) 2024-05-01
US10039811B2 (en) 2018-08-07
US20170143806A1 (en) 2017-05-25
TWI649423B (zh) 2019-02-01
US9527888B2 (en) 2016-12-27
US20220331407A1 (en) 2022-10-20
WO2013167299A1 (en) 2013-11-14
US20170081376A1 (en) 2017-03-23
EP3428181B1 (en) 2025-10-08
TWI719344B (zh) 2021-02-21
US11622998B2 (en) 2023-04-11
CN108949717B (zh) 2023-06-20
US9540419B2 (en) 2017-01-10
US20240000902A1 (en) 2024-01-04
CN104507961B (zh) 2018-08-14
US12168039B2 (en) 2024-12-17
JP2018039806A (ja) 2018-03-15
TW201800105A (zh) 2018-01-01
KR20150056670A (ko) 2015-05-26
EP3428181C0 (en) 2025-10-08
US20190030137A1 (en) 2019-01-31
ES2691070T3 (es) 2018-11-23
KR20210025132A (ko) 2021-03-08
JP2024052952A (ja) 2024-04-12
CN108478786B (zh) 2023-01-10
EP2850097B1 (en) 2018-07-25
US11369665B2 (en) 2022-06-28
ES3046661T3 (en) 2025-12-02
US10960056B2 (en) 2021-03-30
CN104507961A (zh) 2015-04-08
CN108841802A (zh) 2018-11-20
US20190192638A1 (en) 2019-06-27
JP2018172395A (ja) 2018-11-08
WO2013167574A1 (en) 2013-11-14
US10888606B2 (en) 2021-01-12
KR20150014483A (ko) 2015-02-06
CN108841802B (zh) 2023-06-09
CN108478786A (zh) 2018-09-04
EP3428181A2 (en) 2019-01-16
US20150099693A1 (en) 2015-04-09
KR102043426B1 (ko) 2019-11-12
JP6923485B2 (ja) 2021-08-18
US12156902B2 (en) 2024-12-03
TW201406959A (zh) 2014-02-16
JP6546232B2 (ja) 2019-07-17
TW201406958A (zh) 2014-02-16
TW201925465A (zh) 2019-07-01
US20240091320A1 (en) 2024-03-21
CN104507962A (zh) 2015-04-08
KR101685551B1 (ko) 2016-12-12
KR20150008838A (ko) 2015-01-23
JP2015521039A (ja) 2015-07-27
US11857607B2 (en) 2024-01-02
TWI665304B (zh) 2019-07-11
US20150099692A1 (en) 2015-04-09
CN108949717A (zh) 2018-12-07
CN115927242A (zh) 2023-04-07
TW202246301A (zh) 2022-12-01
KR102578891B1 (ko) 2023-09-15
EP2850097A1 (en) 2015-03-25
WO2013167298A1 (en) 2013-11-14
CN104507962B (zh) 2018-06-05
US20230293644A1 (en) 2023-09-21
US10206981B2 (en) 2019-02-19
JP7757448B2 (ja) 2025-10-21
ES2750003T3 (es) 2020-03-24

Similar Documents

Publication Publication Date Title
JP6466833B2 (ja) 抗炎症活性を有するペプチド、及びそれを含む組成物
JP7741218B2 (ja) 抗炎症活性を有するペプチド、及びそれを含む組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160315

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170906

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180606

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181211

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190110

R150 Certificate of patent or registration of utility model

Ref document number: 6466833

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250